AU2020406862A1 - Antigen-binding domain binding to PSMA - Google Patents

Antigen-binding domain binding to PSMA Download PDF

Info

Publication number
AU2020406862A1
AU2020406862A1 AU2020406862A AU2020406862A AU2020406862A1 AU 2020406862 A1 AU2020406862 A1 AU 2020406862A1 AU 2020406862 A AU2020406862 A AU 2020406862A AU 2020406862 A AU2020406862 A AU 2020406862A AU 2020406862 A1 AU2020406862 A1 AU 2020406862A1
Authority
AU
Australia
Prior art keywords
seq
cells
antigen
cell
lcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020406862A
Other languages
English (en)
Inventor
Shaun CORDOBA
Marco DELLA PERUTA
Mathieu FERRARI
Alexander KINNA
Shimobi ONUOHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of AU2020406862A1 publication Critical patent/AU2020406862A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020406862A 2019-12-20 2020-12-18 Antigen-binding domain binding to PSMA Abandoned AU2020406862A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919019.8 2019-12-20
GBGB1919019.8A GB201919019D0 (en) 2019-12-20 2019-12-20 Antigen-binding domain
PCT/GB2020/053289 WO2021123810A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to psma

Publications (1)

Publication Number Publication Date
AU2020406862A1 true AU2020406862A1 (en) 2022-06-16

Family

ID=69322734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020406862A Abandoned AU2020406862A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to PSMA

Country Status (8)

Country Link
US (1) US12496314B2 (cg-RX-API-DMAC7.html)
EP (1) EP4076509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7600240B2 (cg-RX-API-DMAC7.html)
CN (1) CN114828879A (cg-RX-API-DMAC7.html)
AU (1) AU2020406862A1 (cg-RX-API-DMAC7.html)
CA (1) CA3161844A1 (cg-RX-API-DMAC7.html)
GB (1) GB201919019D0 (cg-RX-API-DMAC7.html)
WO (1) WO2021123810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202007044D0 (en) * 2020-05-13 2020-06-24 Autolus Ltd Method
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
JP7855148B2 (ja) 2023-02-10 2026-05-07 アムニクス ファーマシューティカルズ, インコーポレイテッド 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US8691771B2 (en) * 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
US20180016346A1 (en) 2015-01-08 2018-01-18 Kyowa Hakko Kirin Co., Ltd Bispecific antibody binding to trailr2 and psma
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
CN109641037B (zh) * 2016-04-13 2022-09-06 西安奥瑞单抗生物技术有限公司 抗psma抗体及其用途
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
KR20200130709A (ko) * 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
BR112020018049A2 (pt) 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
CN108640999B (zh) 2018-03-27 2021-08-13 广东万海细胞生物科技有限公司 一种靶向表达psma表面抗原的细胞的嵌合抗原受体
CN110526976A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN110526984A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用

Also Published As

Publication number Publication date
JP2025015730A (ja) 2025-01-30
GB201919019D0 (en) 2020-02-05
JP2023507740A (ja) 2023-02-27
CA3161844A1 (en) 2021-06-24
CN114828879A (zh) 2022-07-29
WO2021123810A1 (en) 2021-06-24
US12496314B2 (en) 2025-12-16
EP4076509A1 (en) 2022-10-26
US20240252534A1 (en) 2024-08-01
JP7600240B2 (ja) 2024-12-16

Similar Documents

Publication Publication Date Title
US12006371B2 (en) Humanized anti-MUC1* antibodies
US12129291B2 (en) Anti-GPC3 antibody
AU2016342560B2 (en) Receptor
AU2019400152B2 (en) Novel scFv amino acid sequence, chimeric antigen receptor containing same and application thereof
US12496314B2 (en) Antigen-binding domain
US11643453B2 (en) Cell
CN107880128B (zh) 一种抗cd19的全人源抗体或抗体片段及其方法和应用
EP3245231B1 (en) Antibodies and chimeric antigen receptors specific for ror1
WO2021048564A2 (en) Antigen-binding domain
CN111479918A (zh) 细胞
JP7728477B2 (ja) 抗ror1抗体及びror1を標的とする操作された細胞
CN114409781B (zh) 全人源抗人cd40单克隆抗体及其应用
CN120435310A (zh) 对δ样配体3(DLL3)具有特异性的抗体和嵌合抗原受体
US20250312453A1 (en) Antibody targeting ccr8 and its applications
WO2025133609A1 (en) Polypeptide binding glypican-3
CN113527491A (zh) 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用
WO2023078431A1 (zh) 一种特异性结合间皮素的合成t细胞受体抗原受体及其应用
WO2026098304A1 (zh) 抗pd-1抗体、car-t细胞、其制备方法及应用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ONUOHA, SHIMOBI; FERRARI, MATHIEU; DELLA PERUTA, MARCO; KINNA, ALEXANDER AND CORDOBA, SHAUN

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application